Nucor Surges After Q3 Beat as Analysts Chase Targets Higher

Nucor delivered a strong Q3 result last week, and the stock has responded with its best two-day run in months, leaving analysts scrambling to update numbers that now look too conservative.

The stock closed Tuesday at $270.79, up 5.2% on the day and 3.6% over the week. That compares well against its closest peers: STLD added just under 1% on the week, while RS gained 3.7% and CMC slipped 1.6%. The post-earnings move confirms what options traders had been signalling beforehand: the put/call ratio came into results at 0.77, its least defensive reading of the past year, well below the 20-day mean of 0.80. Call buyers were positioned for the upside, and they were right.

The earnings reaction itself was measured but positive. The stock gained roughly 4.9% on October 26, the day the Q3 results crossed. That follows a much more muted 0.5% gain after the prior quarter's print in July, suggesting the latest results carried more weight with investors. Wikipedia attention for the company spiked to a z-score of 2.1 against its own 90-day history, the highest retail-attention reading in the dataset's recent window, consistent with the post-earnings traffic that typically follows a surprise move in a large industrial name.

The analyst community moved quickly. Barclays raised its target to $320 from $306 on Wednesday, the same day Wells Fargo's Timna Tanners lifted her number to $305 from $280, keeping Overweight on both. The Street's mean price target now stands at $288, which still sits roughly 6% above Tuesday's close of $270.79. That gap is narrower than it was before the print, when targets clustered below the mid-$290s, but it still implies the consensus view is that the post-earnings move has not fully closed the discount. JPMorgan had trimmed to $296 earlier in the month, before the result, a cut that now looks cautious given where the stock has landed. The valuation picture has shifted alongside: the trailing P/E has moved to 13.1 and EV/EBITDA to 8.3, both up meaningfully over the past 30 days as the share price recovered ground.

Short interest is worth a brief mention, though the borrow market has nothing dramatic to report. Shorts added positions last week at a pace roughly two standard deviations above the typical weekly move for this stock, with short interest rising to 2.1% of the free float from around 1.9% the week before. The absolute level remains low. Borrow availability is entirely unconstrained, with shares available to lend dwarfing outstanding shorts, and cost to borrow is 0.40%, up from a low base but still negligible. The uptick in short interest looks more like tactical repositioning after the run-up than a conviction bet against the company's fundamentals. The ORTEX short score sits at 33.4, in the lower half of the universe, consistent with a stock where the short case has limited traction.

Insider activity in the 90-day window remains net negative at roughly $17.3m in sales, led by CEO Leon Topalian, who sold just over $7m worth of shares in August at prices around $269. Those sales now look well-timed relative to the stock's trajectory through the late summer, though the stock has since recovered to similar levels. No open-market purchases are on record in the recent window, which is worth noting alongside an EPS momentum factor score in the 90th percentile and a dividend factor score of 93: a company whose data looks strong but whose insiders chose to lighten rather than add.

The next earnings date is November 5, just eight days away, which means attention will turn quickly to the Q4 setup: whether the steel pricing environment that supported Q3 has held into the final months of the year, and whether the analyst target upgrades that followed this week's result prove durable or front-run the next print.